Welcome to our dedicated page for EMBCV news (Ticker: EMBCV), a resource for investors and traders seeking the latest updates and insights on EMBCV stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect EMBCV's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of EMBCV's position in the market.
Embecta Corp. (NASDAQ: EMBC) has declared a quarterly cash dividend of $0.15 for each share of its common stock. This dividend will be paid on September 14, 2022 to stockholders of record as of August 26, 2022. As a leading pure-play diabetes care company, Embecta aims to support individuals with diabetes through innovative solutions, leveraging nearly a century of experience in insulin delivery.
Embecta Corp. (NASDAQ: EMBC) announced it will report its third-quarter financial results for fiscal year 2022 on August 15, 2022. The company’s management will hold a conference call at 8:00 a.m. ET to discuss results and provide an operational update. Embecta is positioned as a significant player in diabetes care following its spin-off from Becton, Dickinson and Company on April 1, 2022. The live webcast of the call will be accessible through the company’s investor relations website.
Embecta Corp. (Nasdaq: EMBC) reported Q2 2022 revenues of $274.5 million, a decline of 3.4% year-over-year. U.S. revenues dropped 5.8%, while international revenues saw a slight decrease of 0.8%. Net income was $79.6 million, down from $107.9 million in Q2 2021. Gross profit margin rose to 69.7%. For the first half of 2022, total revenue was $563.8 million, down 1.0%, with a net income of $178.4 million. The company anticipates a significant revenue decrease of about 7% for the second half of FY 2022, projecting revenues around $555 million due to continuing supply chain challenges.
Embecta Corp. (Nasdaq: EMBC) has announced its participation in two significant investor conferences. The 2022 RBC Capital Markets Global Healthcare Conference will feature a fireside chat on May 18 at 9:30 a.m. ET at the Intercontinental NY Barclay Hotel. Furthermore, the Piper Sandler Ophthalmology and Diabetes Symposium will include a virtual fireside chat on May 25 at 12:00 p.m. ET. Both presentations will be available for replay on the company’s investor relations website.
With nearly 100 years of experience in diabetes care, Embecta aims to empower diabetes patients worldwide.
Embecta Corp. (NASDAQ: EMBC) announced it will release its financial results for Q2 of fiscal 2022 on May 13, 2022, before market opening. A conference call is set for 8:00 AM ET to discuss the results, provide business updates, and share financial guidance for 2022. Participants can join via phone or a live webcast on the company's investor website. An audio replay will be available post-call. Embecta, focused on diabetes care, leverages a century of insulin delivery experience to support individuals with diabetes.
Embecta Corp. has launched as a leading global diabetes care company, with a history stretching back to 1924. As the largest producer of diabetes injection devices, Embecta manufactures around 8 billion devices annually, serving approximately 30 million patients worldwide. The company estimates the insulin delivery market to be valued at $6 billion to $8 billion per year. With operations spanning over 100 countries and a dedicated workforce of 2,000, Embecta aims to enhance shareholder value through strategic independence and innovation in diabetes care.